At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 852 enrolled
Drug / intervention
Bimekizumab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Active Reference (Adalimumab) Study Evaluating the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
In Brief
A Phase 3 clinical trial evaluating Bimekizumab, Adalimumab, and 1 other intervention for Psoriatic Arthritis. Completed, enrolled 852 participants across 136 sites in 14 countries.
Detailed Summary
This is a study to demonstrate the clinical efficacy, safety and tolerability of bimekizumab administered subcutaneously (sc) compared with placebo in the treatment of subjects with active Psoriatic Arthritis (PsA).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriatic Arthritis
CountriesAustralia, Belgium, Canada, Czechia, France, Germany, Hungary, Italy, Japan, Poland, Russia, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2020202120222023202420252026
First PostedMar 2019
Enrollment StartApr 2019
Primary CompletionAug 2021
Study CompletionJul 2022
TodayJul 2026
First PostedMar 29, 2019
Enrollment StartApr 3, 2019
Primary CompletionAug 17, 2021
Study CompletionJul 11, 2022
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 7.3 years ago
Interventions
Bimekizumabdrug
Subjects will receive bimekizumab at pre-specified time-points.
Adalimumabdrug
Adalimumab will be administered according to the labeling recommendations.
Placeboother
Subjects will receive placebo at pre-specified time-points.